Robert Floyd, DO
Internal Medicine · Bloomfield, IANPI 1275514028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$326
- AbbVie$238
- Amgen$227
- Pfizer$227
- Novo Nordisk$211
- AstraZeneca$188
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 18 | $326 |
| AbbVie(2 entities) | 13 | $238 |
| Amgen | 15 | $227 |
| Pfizer | 14 | $227 |
| Novo Nordisk | 13 | $211 |
| AstraZeneca | 12 | $188 |
| Lilly USA, LLC | 8 | $153 |
| Merck | 10 | $150 |
| Mylan Specialty L.p. | 9 | $149 |
| Johnson & Johnson | 9 | $135 |
| Bayer | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $129 |
| GSK | 9 | $125 |
| Abbott | 6 | $119 |
| Insulet Corporation | 5 | $97 |
| Novartis | 4 | $95 |
| Medtronic(2 entities) | 4 | $82 |
| Astellas Pharma US Inc | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Boston Scientific | 3 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $17 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,375 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 260 | $297,791 |
| OzempicSemaglutide | 269 | $295,861 |
| JardianceEmpagliflozin | 290 | $226,557 |
| Tresiba Flextouch U-200Insulin Degludec | 179 | $152,457 |
| EliquisApixaban | 250 | $151,808 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 134 | $104,304 |
| XareltoRivaroxaban | 58 | $70,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $68,746 |
| TrulicityDulaglutide | 30 | $42,979 |
| MyrbetriqMirabegron | 80 | $40,727 |
| FarxigaDapagliflozin Propanediol | 34 | $35,986 |
| TradjentaLinagliptin | 38 | $32,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $28,825 |
| JanuviaSitagliptin Phosphate | 50 | $27,773 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $25,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Stiolto Respimat, Glyxambi | $326 | $397,840523 claims |
| Lilly USA, LLCMounjaro, Trulicity | $153 | $340,770290 claims |
| Novo NordiskOzempic, Rybelsus | $211 | $313,871281 claims |
| PfizerEliquis, Premarin | $227 | $161,621283 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $125 | $120,773198 claims |
| Johnson & JohnsonXarelto, Invokana | $135 | $81,14972 claims |
| MerckJanuvia, Belsomra, Janumet Xr, Janumet, Verquvo | $150 | $78,397157 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $188 | $51,55446 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $40,72780 claims |
| AbbVieLinzess, Restasis | $238 | $20,20831 claims |
| NovartisEntresto | $95 | $16,96313 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $12,54514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Bloomfield
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Ali SaeedCedar Rapids$17K
- Lazaro RabangUrbandale$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.